Form 4: Integrated BioPharma Co-CEO Exercises Stock Options, Acquires 55,555 Shares

Integrated BioPharma's Co-Chief Executive Officer, Riva Sheppard, exercised stock options to acquire 55,555 common shares at $0.09 per share.

Summary

• Riva Sheppard, Co-Chief Executive Officer of Integrated BioPharma Inc., exercised stock options on November 25, 2024.
• This transaction resulted in the acquisition of 55,555 common stock shares at a price of $0.09 per share.
• The stock options were granted on June 2, 2015, and were set to expire on June 2, 2025.
• Following the transaction, Ms. Sheppard directly owns 1,329,022 common shares and 144,445 stock options.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction. It is neither particularly positive nor negative, but the exercise of options by a CEO is generally seen as a neutral to slightly positive sign.

Positives

• The exercise of stock options by a top executive can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure required by the SEC.

Comparison to Industry Standards

• Stock option exercises are a common form of executive compensation in publicly traded companies.
• The reporting of these transactions via SEC Form 4 is a standard practice across the industry.
• The size of the transaction is not unusual for a Co-CEO of a company of this size.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates confidence from a top executive.

Key Dates

Keywords

stock options, insider trading, executive compensation, common stock, Integrated BioPharma, Riva Sheppard